av-133
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 30, 2023 (NCT07265596)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Mechanism of action
- Synaptic vesicular amine transporterRadiopharmaceutical
SLC18A2 radiopharmaceutical
Chemistry & pharmacology
- Payload
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07265596 | Phase 2 | Oct 30, 2023 | Institute for Neurodegenerative Disorders, Michael J. Fox Foundation for Parkinson's Research |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Institute for Neurodegenerative Disorders | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Michael J. Fox Foundation for Parkinson's Research | Academic/Hospital | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1